LCCC 1128: Open Label Phase II Trial of the BRAF Inhibitor (Dabrafenib) and the MEK Inhibitor (Trametinib) in Unresectable Stage III and Stage IV BRAF Mutant Melanoma; Correlation of Resistance With the Kinome and Functional Mutations

Clinical trial NCT01726738 · COMPLETED

Trial details

NCT number: NCT01726738
Sponsor: UNC Lineberger Comprehensive Cancer Center
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Stage III Melanoma Stage IV Melanoma Unresectable Melanoma BRAF Mutant Melanoma

Start date: 2013-04-04
Primary completion: 2017-11-03
Enrollment: 17

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.